Skip to main content

Identifying Patients

Not actual DUPIXENT patients.

Open Up a World
FOR INDICATED UNCONTROLLED PATIENTS WITH MODERATE-TO-SEVERE ASTHMA

Not actual DUPIXENT patients.

Open Up a World
FOR INDICATED UNCONTROLLED PATIENTS WITH MODERATE-TO-SEVERE ASTHMA

Look for the signs and symptoms of
uncontrolled asthma1

Two or more bursts
of
OCS in a year

Frequent
exacerbations

Cough

Wheezing

Shortness
of breath

Frequent
albuterol use

Nighttime awakening
due to asthma

Activity limitation
due to asthma

Evidence of type 2 inflammation is identified by one or more of the following biomarkers1,2:

  • EOS ≥150 cells/µL and/or
  • IgE ≥30 IU/mLa and/or
  • FeNO ≥20 ppb

aPlus ≥1 positive perennial-aeroallergen–specific IgE ≥0.35 kU/L at baseline.2

DUPIXENT is indicated as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with
moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma.
Limitations of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.

Patients requiring maintenance OCS may also have underlying type 2 inflammation.1

TYPE 2 INFLAMMATION MAY CONTRIBUTE TO WORSENING
SYMPTOMS IN ASTHMA1

Help appropriate patients benefit from the only biologic that
directly inhibits IL-4 and IL-13 signaling3,*

*The mechanism of dupilumab action has not been definitively established.

Patient profiles are representative and are not actual DUPIXENT patients.

I wish I didn’t have
to go to urgent care
so often because of
asthma attacks.

Hosana’s
symptoms and
clinical findings

  • Symptoms of productive cough, wheezing, and chest tightness/shortness of breath
  • ≥2 exacerbations in the past year
  • On daily medium-to-high dose ICS/LABA
  • Elevated EOS ≥150 cells/μL (could be impacted by recent OCS bursts)
  • History of elevated IgE
  • Reduced lung function (percent predicted FEV1: 64%)

Explore DUPIXENT
data for a patient
like Hosana

Up to 81% reduction in severe
exacerbationsb through Week 24

with DUPIXENT 300 mg Q2W + SOC (n=64) vs placebo + SOC (n=68) (0.20 vs 1.04; rate ratio: 0.19 [95% CI: 0.07, 0.56]) (baseline blood EOS ≥300 cells/µL, DRI12544, secondary endpoint).3

~72% of the total FEV1 improvement
was seen as early as Week 2

470 mL improvement from baseline in
pre-bronchodilator FEV1 at Week 52 compared to baseline FEV1 of 1.78 L with DUPIXENT 200 mg Q2W + SOC (n=264) vs 170 mL with placebo + SOC (n=148) (baseline blood EOS ≥300 cells/µL, QUEST, secondary endpoint).3,4

480 mL improvement from baseline in
pre-bronchodilator FEV1 at Week 52 with DUPIXENT 300 mg Q2W + SOC (n=277) vs 230 mL with placebo + SOC (n=142) (baseline blood EOS ≥300 cells/μL, QUEST, secondary endpoint).3,4

FIND OUT MORE ABOUT HOW DUPIXENT
CAN HELP PATIENTS LIKE HOSANA

I’m frustrated
with recent
weight gain and
sleep disturbance
due to frequent
OCS use.

Bobby’s
symptoms and
clinical findings

  • Symptoms of productive cough, wheezing, and chest tightness/shortness of breath
  • ≥2 OCS bursts in the past year
  • Nighttime awakenings due to asthma
  • On daily medium-to-high dose ICS/LABA
  • Elevated EOS ≥150 cells/μL (could be impacted by recent OCS bursts)

Explore DUPIXENT
data for a patient
like Bobby

86% of patients reduced or eliminated
their OCS dose at Week 24

with DUPIXENT 300 mg Q2W + SOC (n=103) vs 68% with placebo + SOC (n=107) (no biomarker requirement, ITT population, VENTURE, secondary endpoint).3,5

70% significant mean reduction in OCS dose (median 100%) from baseline at Week 24 with DUPIXENT 300 mg Q2W + SOC (n=103) (95% CI: 60%, 80%) vs 42% (median 50%) with placebo + SOC (n=107) (no biomarker requirement, ITT population, VENTURE, primary endpoint).3,5

DUPIXENT IS THE ONLY
BIOLOGIC SPECIFICALLY
INDICATED FOR OCS-DEPENDENT
ASTHMA PATIENTS3

FIND OUT MORE ABOUT HOW DUPIXENT
CAN HELP PATIENTS LIKE BOBBY

I just want to
breathe better
while playing with
my friends at
recess.

Juana’s
symptoms and
clinical findings

  • Symptoms of productive cough, wheezing, and chest tightness/shortness of breath
  • ≥2 exacerbations in the past year
  • Nighttime awakenings due to asthma
  • On daily medium-to-high dose ICS/LABA
  • Elevated EOS ≥150 cells/μL (could be impacted by recent OCS bursts)
  • Reduced lung function (percent predicted FEV1: 74%)

Explore DUPIXENT
data for a patient
like Juana

Up to 65% reduction in severe
exacerbationsc through Week 52

with DUPIXENT 100 mg/200 mg Q2W + SOC (n=175) vs placebo + SOC (n=84) (0.24 vs 0.67; rate ratio: 0.35 [95% CI: 0.22, 0.56]); P<0.001 (baseline blood EOS ≥300 cells/µL, VOYAGE, primary endpoint).6,c

~2X IMPROVEMENT IN PERCENT
PREDICTED PRE-BRONCHODILATOR FEV1

was seen with DUPIXENT at Week 12 vs placebo (VOYAGE, key secondary endpoint).6

5.32% improvement in percent predicted pre-bronchodilator FEV1 in children aged 6-11 years with EOS ≥300 cells/μL (n=175) at Week 12 with DUPIXENT 100 mg/200 mg Q2W + SOC (n=168) vs placebo + SOC (n=80).6

FIND OUT MORE ABOUT HOW DUPIXENT
CAN HELP PATIENTS LIKE Juana

 

bDRI12544/QUEST: Severe exacerbations were defined as deterioration of asthma requiring the use of SCS for at least 3 days or hospitalization or ED visit due to asthma
that required SCS.3

cVOYAGE: Severe exacerbations were defined as deterioration of asthma requiring the use of SCS for at least 3 days or hospitalization or ED visit due to asthma
that required SCS.6

ED, emergency department; EOS, eosinophils; FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 second; ICS, inhaled corticosteroid;
ITT, intention-to-treat; LABA, long-acting beta agonist; OCS, oral corticosteroid; Q2W, once every 2 weeks; SCS, systemic corticosteroid; SOC, standard of care.

SEE THE EFFICACY AND SAFETY OVERVIEW